ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.163,52
-0,41%
S&P 500
5.464,62
-0,16%
Dow Jones
39.150,33
0,04%
Euro vs US Dollar
1,06925
0,00%
Bitcoin
64.070,60
-0,27%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Purple Biotech Ltd (PPBT)

  7. Purple Biotech Ltd (PPBT) News

PPBT

Purple Biotech (PPBT)

Purple Biotech Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PPBT
DatumZeitQuelleÜberschriftSymbolFirma
20/06/202415h16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
04/06/202422h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
03/06/202412h21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
01/06/202414h00GlobeNewswire Inc.Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic CancerNASDAQ:PPBTPurple Biotech Ltd
21/05/202413h40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
21/05/202413h30GlobeNewswire Inc.Purple Biotech Reports First Quarter 2024 Financial ResultsNASDAQ:PPBTPurple Biotech Ltd
25/04/202413h00GlobeNewswire Inc.Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual MeetingNASDAQ:PPBTPurple Biotech Ltd
28/03/202412h00GlobeNewswire Inc.Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024NASDAQ:PPBTPurple Biotech Ltd
14/03/202412h30GlobeNewswire Inc.Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform TechnologyNASDAQ:PPBTPurple Biotech Ltd
06/03/202422h06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
05/03/202422h00Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:PPBTPurple Biotech Ltd
05/03/202413h58Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
05/03/202413h55GlobeNewswire Inc.Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:PPBTPurple Biotech Ltd
27/02/202413h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
27/02/202413h00GlobeNewswire Inc.Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024NASDAQ:PPBTPurple Biotech Ltd
13/02/202413h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
13/02/202413h00GlobeNewswire Inc.Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 TrialNASDAQ:PPBTPurple Biotech Ltd
01/02/202413h40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
01/02/202413h40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
01/02/202413h30GlobeNewswire Inc.Purple Biotech Reaches Recommended Phase 2 Dose for NT219NASDAQ:PPBTPurple Biotech Ltd
26/01/202422h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
20/12/202314h06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
20/12/202314h05GlobeNewswire Inc.Purple Biotech Appoints Dr. Yael Margolin to its Board of DirectorsNASDAQ:PPBTPurple Biotech Ltd
14/12/202313h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
14/12/202312h50GlobeNewswire Inc.Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer TrialNASDAQ:PPBTPurple Biotech Ltd
21/11/202313h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
21/11/202312h50GlobeNewswire Inc.Purple Biotech Reports Third Quarter 2023 Financial ResultsNASDAQ:PPBTPurple Biotech Ltd
15/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PPBTPurple Biotech Ltd
14/11/202322h13Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PPBTPurple Biotech Ltd
13/11/202322h11Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:PPBTPurple Biotech Ltd
 Showing the most relevant articles for your search:NASDAQ:PPBT

Kürzlich von Ihnen besucht

USOTC
BRIPF
Brookfield Infrastructur... (PK)
LATK
BICOBTC
Biconomy Token
TG
217A
VNET
NASDAQI
OMXCCAPXTRYGPI
OMX Copenhagen Cap Index...
COIN
WITKNUSD
HITB
HUNTUSDT
HUNT Token
EU
TOF
VanEck ETFs NV
COIN
EJOYETH
UNSW3
LEASHUSDT
DOGE KILLER
USOTC
DURCF
Duratec (PK)
BIT
P1W4B5
NLBNPIT1W4B5 20991231 33...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten